V Square Quantitative Management LLC Has $12.55 Million Position in Eli Lilly and Company (NYSE:LLY)

V Square Quantitative Management LLC raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 9.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 14,168 shares of the company’s stock after acquiring an additional 1,266 shares during the period. Eli Lilly and Company comprises approximately 1.8% of V Square Quantitative Management LLC’s portfolio, making the stock its 5th biggest holding. V Square Quantitative Management LLC’s holdings in Eli Lilly and Company were worth $12,552,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the business. First Community Trust NA lifted its stake in shares of Eli Lilly and Company by 390.0% in the 1st quarter. First Community Trust NA now owns 245 shares of the company’s stock valued at $191,000 after acquiring an additional 195 shares during the last quarter. Gunderson Capital Management Inc. lifted its position in Eli Lilly and Company by 6.7% in the first quarter. Gunderson Capital Management Inc. now owns 19,905 shares of the company’s stock valued at $15,485,000 after purchasing an additional 1,247 shares during the last quarter. BTC Capital Management Inc. purchased a new stake in shares of Eli Lilly and Company during the first quarter valued at approximately $1,432,000. PFW Advisors LLC grew its holdings in shares of Eli Lilly and Company by 1.7% in the first quarter. PFW Advisors LLC now owns 982 shares of the company’s stock worth $764,000 after purchasing an additional 16 shares during the last quarter. Finally, Allied Investment Advisors LLC purchased a new position in shares of Eli Lilly and Company in the first quarter worth $209,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Up 0.1 %

NYSE:LLY opened at $917.86 on Friday. The firm has a market capitalization of $872.34 billion, a P/E ratio of 135.18, a PEG ratio of 2.79 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. Eli Lilly and Company has a one year low of $547.61 and a one year high of $972.53. The company’s 50-day simple moving average is $921.21 and its 200 day simple moving average is $857.37.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. As a group, analysts forecast that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on LLY. Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. BMO Capital Markets raised their target price on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Jefferies Financial Group boosted their price target on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a report on Monday, June 24th. Wells Fargo & Company increased their price objective on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 target price on shares of Eli Lilly and Company in a research note on Monday, September 16th. Three equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $986.00.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.